Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.
| Quarter | Letter Date | Fund Name | QTD | YTD | Tickers | Themes | Quick Take |
|---|---|---|---|---|---|---|---|
Buyside Digest is not affiliated with, and does not endorse, Orbis Global Equity Fund. This analysis is provided for institutional research purposes only and is not investment advice.
"Orbis has allocated ~8% of its Global Equity Strategy to deeply discounted, high-innovation biotech companies (Alnylam, Genmab, Insmed, and CRISPR) that offer attractive, idiosyncratic value in an otherwise expensive and concentrated global market."
Orbis' Q3 2025 commentary focuses on a significant valuation disconnect in the biotech sector. Chasing AI stocks has left innovative drug discovery companies deeply undervalued. Orbis highlights four key biotech holdings that collectively represent ~8% of the Orbis Global Equity Strategy: Alnylam Pharmaceuticals, Genmab, Insmed, and CRISPR Therapeutics. Each of these companies features a productive R&D engine, disciplined capital allocation by strong management, and robust balance sheets. They are trading at undemanding valuations, offering substantial idiosyncratic upside with well-protected downsides.
Sign in or create a free account to unlock full commentary, extracted equity pitches, and direct outbound manager source links with your 3 quarterly credits.
Algorithmic conviction, macroeconomic posture, and risk appetite signals extracted from this quarterly letter with qualitative explanations.
Market Conviction
High-conviction positioning: Orbis has allocated ~8% of its Global Equity Strategy to deeply discounted, high-innovation biotech companies (Alnylam, Genmab, Insmed, and CRISPR) that offer attractive, idiosyncr...
Growth Outlook
Market outlook remains moderate conviction: Orbis has allocated ~8% of its Global Equity Strategy to deeply discounted, high-innovation biotech companies (Alnylam, Genmab, Insmed, and CRISPR) that offer attractive, idiosyncr...
Risk Appetite
Risk appetite posture is above average conviction: Orbis has allocated ~8% of its Global Equity Strategy to deeply discounted, high-innovation biotech companies (Alnylam, Genmab, Insmed, and CRISPR) that offer attractive, idiosyncr...
Capital Deployment
Manager actively deployed capital into high-conviction opportunities. Orbis has allocated ~8% of its Global Equity Strategy to deeply discounted, high-innovation biotech companies (Alnylam, Genmab, Insmed, and CRISPR) that offer attractive, idiosyncr...
Forward Guidance
Forward guidance signal: Orbis has allocated ~8% of its Global Equity Strategy to deeply discounted, high-innovation biotech companies (Alnylam, Genmab, Insmed, and CRISPR) that offer attractive, idiosyncr...
Language Signal
Tone analysis indicates above average conviction language: Orbis has allocated ~8% of its Global Equity Strategy to deeply discounted, high-innovation biotech companies (Alnylam, Genmab, Insmed, and CRISPR) that offer attractive, idiosyncr...
Perceived Risk
Perceived risk level is evaluated as moderate conviction. Orbis has allocated ~8% of its Global Equity Strategy to deeply discounted, high-innovation biotech companies (Alnylam, Genmab, Insmed, and CRISPR) that offer attractive, idiosyncr...
Opportunity Density
Opportunity density index indicates above average conviction actionable entry points. Orbis has allocated ~8% of its Global Equity Strategy to deeply discounted, high-innovation biotech companies (Alnylam, Genmab, Insmed, and CRISPR) that offer attractive, idiosyncr...
Time Horizon
Investment time horizon reflects a high conviction orientation. Orbis has allocated ~8% of its Global Equity Strategy to deeply discounted, high-innovation biotech companies (Alnylam, Genmab, Insmed, and CRISPR) that offer attractive, idiosyncr...
